Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Response kinetics and factors predicting survival in core-binding factor leukemia.
Leukemia. 2018 Dec;32(12):2698-2701. doi: 10.1038/s41375-018-0158-1. Epub 2018 Jun 8.
Leukemia. 2018.
PMID: 29884905
Clinical Trial.
No abstract available.
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY.
Maiti A, et al. Among authors: maduike re.
Cancer. 2021 Nov 15;127(22):4213-4220. doi: 10.1002/cncr.33814. Epub 2021 Aug 3.
Cancer. 2021.
PMID: 34343352
Free PMC article.
Item in Clipboard
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G.
Jabbour E, et al. Among authors: maduike r.
Cancer. 2017 Feb 15;123(4):629-637. doi: 10.1002/cncr.30383. Epub 2016 Oct 14.
Cancer. 2017.
PMID: 27741352
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite